Drugs / Naftifine

Regulatory milestones approvals, filings & regulatory actions · 6 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (5) US (FDA) NAFTIN 1989-04-05 – 2016-11-10 fda.gov
Approved US (FDA) NAFTIN 1988-02-29 fda.gov

Trials 13 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT02335255 Jun 2014 → May 2018 tinea pedis Sun Pharmaceutical Industries, Inc. Completed No outcome recorded
Phase 1 NCT02132260 Aug 2013 → Feb 2014 tinea pedis Sun Pharmaceutical Industries, Inc. Completed No outcome recorded
Phase 1 NCT01580891 May 2012 → Mar 2013 tinea pedis Sun Pharmaceutical Industries, Inc. Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00253305 Sep 2005 → ? tinea unguium MediQuest Therapeutics Completed No outcome recorded
Phase 36 trials
Phase 3 NCT02633813 Mar → Nov 2015 tinea pedis Genzum Life Sciences Completed No outcome recorded
Phase 3 NCT01885156 Aug → Nov 2013 dermatophytosis of groin and perianal area, tinea pedis Merz North America, Inc. Completed No outcome recorded
Phase 3 NCT01289015 Feb → Nov 2011 tinea pedis Merz North America, Inc. Completed No outcome recorded
Phase 3 NCT01290341 Feb → Nov 2011 tinea pedis Merz North America, Inc. Completed No outcome recorded
Phase 3 NCT00750152 Sep 2008 → Aug 2009 dermatophytosis of groin and perianal area, tinea pedis Merz North America, Inc. Completed No outcome recorded
Phase 3 NCT00750139 Aug 2008 → Aug 2009 tinea pedis Merz North America, Inc. Completed No outcome recorded
Phase 43 trials
Phase 4 NCT02227290 Aug 2014 → Nov 2015 tinea corporis Merz North America, Inc. Completed No outcome recorded
Phase 4 NCT02466867 Jan 2014 → Oct 2015 tinea corporis Merz North America, Inc. Completed No outcome recorded
Phase 4 NCT01712360 Oct 2012 → Nov 2013 dermatophytosis of groin and perianal area, tinea pedis Merz North America, Inc. Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05363449 Comparator Feb 2022 → Nov 2023 dermatophytosis of groin and perianal area, tinea pedis Therapeutics, Inc. Completed No outcome recorded
Phase 21 trial
Phase 2 NCT02658292 Comparator ? → Jul 2016 dermatophytosis of scalp or beard Merz North America, Inc. Withdrawn No outcome recorded

Evidence & citations 14 cited values

Every value below carries the sentence it was read from. 17 sources stand behind the page.

FieldValueCited text
Known as Naftifine “An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftin® (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis” NCT02466867
7

Naftifine HCl 2% cream (NAFT-2) is a topical allylamine antifungal agent under development in the United States.” PMID 22052309 Nov 2011

naftifineNCT01712360

NCT02132260

NCT00253305

NCT01580891

NCT02335255

NCT02633813

Known as AW 105-843 ChEMBL registry synonym — accepted as the source's own label CHEMBL626
Known as NAFT-1 “Naftifine 1% cream (NAFT-1) treatment for four weeks and vehicle were also evaluated as a positive control.” PMID 22052309 Nov 2011
Known as NAFT-2 “Naftifine HCl 2% cream (NAFT-2) is a topical allylamine antifungal agent under development in the United States.” PMID 22052309 Nov 2011
Known as NAFT-500 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00750152
Known as NAFT-600 NAFT-600 (naftin 2 % gel)” NCT01290341
1

NCT01289015

Known as NAFT-900 ChEMBL registry synonym — accepted as the source's own label CHEMBL626
Known as Naftifina ChEMBL registry synonym — accepted as the source's own label CHEMBL626
Known as Naftifine HCl Naftifine HCl 2% cream (NAFT-2) is a topical allylamine antifungal agent under development in the United States.” PMID 22052309 Nov 2011
1

Naftifine HCl Cream 1% (Taro Pharmaceuticals Inc.)” NCT01580891

Known as naftifine hydrochloride “The objectives of this study are to evaluate the safety and efficacy of Naftin (naftifine hydrochloride) Cream, 2% applied once daily for 2 weeks, compared to its vehicle in...” NCT02227290
5

“The purpose of this study is to compare the efficacy and safety of the test formulation Naftifine Hydrochloride Gel 2% to Naftin® (Naftifine Hydrochloride) Gel 2% in a six week...” NCT02335255

“An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftin® (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis” NCT02466867

“Naftin® 2% (Naftifine hydrochloride 2%)” NCT02633813

“Naftin (naftifine hydrochloride) Cream” NCT05363449

NCT02658292

Known as naftin “The purpose of this study is to compare the efficacy and safety of the test formulation Naftifine Hydrochloride Gel 2% to Naftin® (Naftifine Hydrochloride) Gel 2% in a six week...” NCT02335255
9

“An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftin® (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis” NCT02466867

Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) applied once-daily for two weeks.” NCT02132260

Naftin® (Naftifine HCl) Cream 1% (Merz Pharmaceuticals)” NCT01580891

Naftin® 2% (Naftifine hydrochloride 2%)” NCT02633813

“NAFT-600 ( naftin 2 % gel )” NCT01289015

NCT02227290

NCT01290341

NCT01885156

NCT05363449

Known as NSC-760068 ChEMBL registry synonym — accepted as the source's own label CHEMBL626
Modality Other / unclassified “topical allylamine antifungal agent” PMID 22052309 Nov 2011
Route Topical topical allylamine cream applied once a day for up to 4 weeks” NCT00750139